Bina Technologies, a self-styled “genomic big-data science company” set up over three years ago to accelerate progress with personalised medicine through its Genomic Analysis Platform, has expanded its advisory board and executive commercial team.
Clinical genomicists Dr Robert Green, Dr Shashikant Kulkarni and Dr Rong Chen, as well as bioinformaticist Dr Mark Gerstein, have joined the Scientific Advisory Board at Bina, which operates out of in Redwood City in California, US.
They will sit alongside existing board members Dr Wing Wong, Professor of Statistics and of Health Research and Policy at Stanford University; Dr. Garry Nolan, Professor of Microbiology and Immunology at the Stanford School of Medicine; and Dr. Wawrzynek, Professor of Engineering and Computer Sciences at University of California, Berkeley.
Bina Technologies was started by a team of Stanford and Berkeley researchers and entrepreneurs. These included founder and chief executive officer Narges Bani Asadi, who followed a computer-science degree at the University of Tehran in Iran with a masters and PhD in electrical engineering at Stanford University.
The Scientific Advisory Board now comprises an “impressive team of experts” across the disciplines of clinical research, genomics, computer science and engineering, and bioinformatics, Bina noted.
Also coming on board are Janet Lankard as vice president of sales and Gianfranco de Feo as vice president of marketing.
“Together, Gianfranco and Janet bring 40 years of deep industry knowledge to Bina,” Asadi commented.
“Each of them has been fundamental in establishing groundbreaking new technologies, such as qPCR and microarrays, in the pharmaceutical, basic and clinical research communities.”
With its expanded Scientific Advisory Board and new commercial leaders, Bina will focus on delivering “powerful, accurate and easy-to-use” analytical tools to drive personalised medicine in clinical research, the company said.